Although curing Parkinson's disease is not yet possible, treatment for movement disorders is a field in transformation. Every year, more insights on underlying causes and techniques for managing symptoms emerge through tireless research and dedicated innovation at Johns Hopkins.
Research at Johns Hopkins never takes place in isolation. Instead, scientists and doctors work together to translate advances in the lab into new therapies for patients with ataxia, dystonia, essential tremor, Parkinson's disease and other movement disorders.
#TomorrowsDiscoveries: Atypical Parkinsonian Disorders
Dr. Alexander Pantelyat and his team collect blood and spinal fluid for genetic and proteomic analyses by using novel brain imaging techniques to distinguish between types of Parkinson’s-plus syndromes and participate in international trials for these devastating diseases.
Animal Study Adds To Evidence Of Parkinson’s Disease Origins In The Gut
Researchers say they have found additional evidence that Parkinson’s disease originates among cells in the gut and travels up the body’s neurons to the brain. The study offers a new, more accurate model in which to test treatments that could prevent or halt Parkinson’s disease progression.
The Morris K. Udall Parkinson's Disease Research Center of Excellence
The Johns Hopkins Morris K. Udall Parkinson's Disease Research Center of Excellence has led the world in explaining fundamental aspects of the neurodegenerative disease. Named in memory of Arizona Congressional Representative Morris K. Udall, who died from Parkinson's disease, the Center at Johns Hopkins was handpicked by the National Institutes of Health as one of three sites to research and fight the disease.
The Institute for Cell Engineering
The Institute for Cell Engineering (known as ICE), established in 2001, brings together top-level scientists in a range of disciplines who are advancing efforts in three highly promising areas: stem cell therapy, nerve regeneration, and immunotherapy. This tremendous resource, the first of its kind on an academic campus, offers an unprecedented opportunity to develop cures for neurological conditions — from spinal cord injury to ALS (Lou Gehrig's disease).